Tammuella Chrisentery-Singleton/LinkedIn
Aug 8, 2026, 20:37
Tammuella Chrisentery-Singleton: What Comes Next for Hemophilia Care With Non-Factor Therapies?
Tammuella Chrisentery-Singleton, Chief Science Officer at American Thrombosis and Hemostasis Network (ATHN), Co- Director Hemostasis and Thrombosis Program at Ochsner Health, shared a post on LinkedIn:
“After the long trip home from ISTH, I’m excited to bring new insights back to the clinic as we think about what comes next for
hemophilia care with non-factor therapies now being available across the world.
Note: This content is intended for healthcare professionals only.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB